HOME >> MEDICINE >> NEWS
Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective

ORLANDO -- The antiplatelet medicine clopidogrel is not only effective in reducing the risk of recurrent heart attack and stroke, it is also extremely cost-effective, according to data presented today by researchers from Emory University at the American Heart Association's Scientific Sessions.

"We have three separate investigations showing uniform results in both the short and long-term use of clopidogrel. Specifically, the use of clopidogrel in addition to aspirin produces a significant risk reduction in recurrent heart attack, stroke or cardiovascular death," says William Weintraub, M.D. FACC, Director, Emory Center for Outcomes Research in the Division of Cardiology, Department of Medicine, Emory University School of Medicine, who presented the data. "The study findings and the cost-effectiveness data suggest that at least one year of therapy with clopidogrel is an attractive value. In fact, we believe it should be the standard of care for this patient population."

The Emory University investigators analyzed the drug's cost-effectiveness ratio in two major clinical studies -- the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial and the CREDO (Clopidogrel for the Reduction of Events During Observation) trial -- as well as a substudy of CURE, called PCI-CURE . Cost-effectiveness ratio is the incremental cost of using an intervention to obtain a unit of effectiveness (such as dollars per life-year gained) compared to another treatment or no treatment.

Based on CURE, the Emory researchers found that the cost-effectiveness ratio was $6,173 per life year gained. PCI-CURE, which evaluated people who received clopidogrel for up to one year after having an angioplasty or stent, demonstrated a cost-effectiveness ratio of $5,910 per life year gained. In CREDO, patients were given a dose of clopidogrel before having an angioplasty or stenting procedures and continued on clopidogrel therapy for up to one year. The cost-effect
'"/>

Contact: Sherry Baker
emoryheartnews@aol.com
404-377-1398
Emory University Health Sciences Center
12-Nov-2003


Page: 1 2

Related medicine news :

1. Antiplatelet drugs: comparison of clopidogrel with aspirin
2. Acupuncture found to lower elevations in blood pressure
3. Proteins found in urine of pregnant women could help diagnose preeclampsia
4. Potential drug target for treating cocaine abuse found
5. Similar results found in both older and younger patients undergoing weight-loss surgery
6. Infectious agent linked to mad cow disease found in organs other than the brain
7. Generation gap found in chronic pain
8. A site for sore eyes: New target for allergies found under the eyelid
9. Chemicals found in cherries may help fight diabetes
10. Thanks for the memories: cinematic portrayal of amnesia is profoundly misleading
11. Very high prevalence of virus linked to cervical cancer found in adolescent women

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: